华邦健康(002004) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥12,359,182,988.15, representing a 13.63% increase compared to ¥10,876,361,873.13 in 2020[48]. - The net profit attributable to shareholders for 2021 was ¥670,048,432.27, a 2.81% increase from ¥651,730,928.90 in 2020[48]. - The net profit after deducting non-recurring gains and losses was ¥610,107,005.64, up 7.23% from ¥568,969,100.22 in 2020[48]. - The company reported a basic earnings per share of ¥0.34 for 2021, a 3.03% increase from ¥0.33 in 2020[48]. - The weighted average return on equity for 2021 was 6.91%, slightly up from 6.87% in 2020[48]. - The company achieved total revenue of CNY 1,235.92 million, an increase of CNY 148.28 million or 13.63% year-on-year[72]. - The company's net profit attributable to shareholders in 2021 was CNY 67.00 million, reflecting a year-on-year increase of CNY 1.83 million or 2.81%[72]. - The pharmaceutical sector contributed CNY 3,003,439,934.04, accounting for 24.30% of total revenue, with a growth of 7.99% compared to the previous year[151]. - The agrochemical new materials sector generated CNY 8,118,733,393.76, representing 65.69% of total revenue, with a significant year-on-year increase of 20.47%[151]. - The tourism services sector (including tea) reported revenue of CNY 513,758,306.04, which is a decline of 12.22% from the previous year[151]. Research and Development - The company has a robust R&D team of nearly 300 people and holds over 180 authorized patents, making it a leading player in the domestic skin drug market[5]. - The company has initiated over 300 product projects in its R&D center, with more than 100 projects implemented in factories, generating significant economic benefits[84]. - The company has developed 2 new Class I drugs and over 20 generic drugs, with 18 formulations passing or deemed equivalent for consistency evaluation[134]. - The number of R&D personnel increased to 1,185 in 2021, a growth of 3.40% compared to 1,146 in 2020[177]. - R&D investment amounted to ¥335,131,044.31 in 2021, reflecting a 2.85% increase from ¥325,836,705.27 in 2020[177]. Product Development and Approvals - The company has successfully obtained drug registration approvals for several new products, including Rivaroxaban tablets and Dexamethasone sodium phosphate injection[6]. - The company has launched functional products in the skin health sector, including medical skin repair dressings and moisturizing creams, targeting multiple distribution channels[76]. - The company has introduced new products in the field of dermatology, including a new formulation of tacrolimus ointment for moderate to severe atopic dermatitis[76]. - The company received approval for the new cardiovascular treatment drug, Rivaroxaban, on January 19, 2021[168]. - The company also received approval for the drug Aminosalicylic Acid and enteric-coated granules for drug-resistant tuberculosis on January 27, 2021[168]. Market Expansion and Strategy - The company is actively developing its CDMO business, leveraging new production capacities to enhance its market position[3]. - The company aims to strengthen its leading position in the prescription market and expand its market share in the outpatient retail sector[3]. - The company has established a comprehensive medical service system through acquisitions and partnerships, including the Beijing Huasheng Rehabilitation Hospital and the Ma'an Skin Hospital chain[15]. - The company has expanded its business scope to include pharmaceuticals, medical services, agricultural chemicals, new materials, and tourism[46]. - The company has achieved significant growth in its outpatient market share by leveraging national healthcare reforms and digital healthcare initiatives[77]. Production Capacity and Facilities - The company is expanding its production capacity with the completion of the Changshou raw material drug production base and Hanjing International raw material drug production base, expected to be operational in 2022[12]. - The company has upgraded its production facilities, increasing capacity by 4-8 times at its Shuitu and Sichuan Mingxin production bases, which are now operational and meet international standards[77]. - The company has completed the construction of its Changshou and Hanzhong raw material production bases, which are expected to commence operations in 2022[77]. - The company has established seven major production bases across five provinces, ensuring sustainable production capabilities[141]. Financial Management and Investments - The profit distribution plan approved by the board is to distribute a cash dividend of 2.20 yuan (including tax) for every 10 shares based on a total of 1,979,919,191 shares[28]. - The total investment amount for the reporting period was CNY 1,662,686,692, representing a 3.12% increase compared to CNY 1,612,386,247 in the same period last year[190]. - The company reported a total of CNY 9,248,336,128.50 in fixed and intangible assets, with significant contributions from long-term equity investments amounting to CNY 4,911,710,825.15[189]. - The company has established a comprehensive cost management system in response to the trend of healthcare cost control, ensuring stable profits through integrated production models and self-supply of key raw materials[138]. Marketing and Sales - The company has established a comprehensive marketing network covering thousands of hospitals and pharmacies nationwide, with over a thousand personnel in its pharmaceutical marketing team[135]. - The company is actively exploring e-commerce channels and has partnered with over ten major pharmaceutical e-commerce platforms[135]. - The company has strengthened its marketing channels, expanding its presence in the outpatient market and covering over 200,000 terminal points, including partnerships with major e-commerce platforms[77]. - The company has established a competitive advantage in the tourism sector through resource integration and brand development, enhancing customer satisfaction and service quality[150]. Agricultural Chemicals and New Materials - The agricultural chemicals segment has a global presence in over 20 countries, with overseas sales accounting for 50.10% of the segment's revenue in 2020, showing an increase in 2021[83]. - The agricultural chemical subsidiary, Yingtai Bio, has over 100 high-quality products in herbicides, fungicides, and insecticides, with strong market competitiveness and leading domestic market share in certain categories[141]. - The new materials business has accumulated 139 patents, including 86 invention patents, and has been recognized as a technology innovation demonstration enterprise[145]. - The company has developed core technologies for efficient and low-toxicity herbicides, focusing on safety, environmental protection, and product quality[122]. Tourism Business - The tourism business includes cableway transportation, scenic area transportation, hotel operations, and tourism performances, primarily relying on famous 5A scenic spots in Yunnan, Shaanxi, Chongqing, and Guangxi[118]. - The company operates three cableways in Yunnan's Jade Dragon Snow Mountain and three in Shaanxi's Taibai Mountain National Forest Park, being the sole operator in these scenic areas[118]. - The tourism services sector (including tea) reported revenue of CNY 513,758,306.04, which is a decline of 12.22% from the previous year[151]. Risk Management - The company has a risk control system in place for its derivative investments, including measures to manage market, liquidity, credit, operational, and legal risks[194]. - The company has established internal control procedures for its forward foreign exchange business to mitigate risks associated with currency fluctuations[194].